Perfecseal Introduces New Packaging Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Perfecseal Introduces New Packaging Products
Perfecseal's high-barrier PVC-free blister-forming web, PerfecForm SkyBlue, is based on polyolefin chemistry, and its new high-barrier flow-wrap specification, PerfecPharm P232, is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment.


Perfecseal has introduced a new high-barrier, PVC-free, blister-forming web, PerfecForm SkyBlue, designed to be cost effective and provide barrier properties to protect all but the highest barrier requirement product applications. This high-barrier blister film is based on polyolefin chemistry, rather than the chlorine chemistry used to produce PVC forming webs.

Unlike other barrier blister films, PerfecForm SkyBlue is manufactured via a co-extrusion process as a symmetrical structure. The thickness of the barrier layer, which is sandwiched between co-polyester, determines the overall barrier performance.

Perfecseal has also introduced a new high-barrier flow-wrap specification, PerfecPharm P232, which is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment. “Perfecseal evaluated this product on high-speed Bosch flow-wrap equipment to assure this product would meet the desired performance level demanded by the healthcare market,” states Georgia Mohr, pharmaceutical director of Perfecseal, in a press release. “The P232 flow wrap material offers a large sealing window (140°C–200°C) and the potential to run at lower temperatures than traditional materials, yet seals hermetically at speeds exceeding 300 ppm.” Once again, Perfecseal delivers packaging solutions based on material science expertise.

Perfecseal, a division of Bemis Company, specializes in healthcare packaging and delivers packaging solutions based on material science expertise.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here